Ignite Creation Date:
2025-12-24 @ 7:34 PM
Ignite Modification Date:
2025-12-29 @ 9:43 PM
Study NCT ID:
NCT01355003
Status:
TERMINATED
Last Update Posted:
2015-08-13
First Post:
2011-05-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Study Overview
Official Title:
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol
Status:
TERMINATED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Merck Sharp \& Dohme Corp (MSD) received exemption from PFDA on conduct of post-marketing surveillance (PMS) study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will collect safety information on the use of GARDASIL™ in the Philippines.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: